A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

Source:http://linkedlifedata.com/resource/pubmed/id/14581347

Clin. Cancer Res. 2003 Oct 15 9 13 4761-71

Download in:

View as

General Info

Authors

Patnaik A, Hammond LA, Goetz A, Rowinsky EK, Eckhardt SG, Mori M, Takimoto CH, Terada K, Schwartz G, Richards H, Izbicka E, Tolcher AA, McCreery H, Gentner L, Rybak ME, Zhang S

Abstract

To assess the feasibility of administering tipifarnib, an oral nonpeptidomimetic competitive inhibitor of farnesyltransferase, in combination with gemcitabine and recommend doses for disease-directed clinical trials. The study also sought to identify drug-drug pharmacokinetic interactions, evaluate effects on protein farnesylation, and seek preliminary evidence for clinical activity.

PMID
14581347

Publication types

Clinical Trial; Research Support, U.S. Gov't, P.H.S.; Clinical Trial, Phase I